Board meeting set to approve Q2 and half-year results

Results View source PDF Explain this filing

AHCL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.0%Reaction day

₹25.56

prior close

₹25.80

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%-3.4% vs market

Pharmaceuticals peers, median of 174sector+1.2%-4.2% vs sector

On the reaction day the stock moved 3.4 pts less than Nifty Microcap 250 and 4.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-5.1

10m

-5.2

15m

-3.9

30m

-2.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.0+0.4-3.4+1.2-4.2

Next day

-4.7pendingpending+3.1-7.8

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 174Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The Board will meet on October 29, 2026, to approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, along with the auditors' limited review report.

Likely market impact

No financial figures are provided yet. Shareholder sentiment may depend on the results and review report announced after the meeting.